All In Biotech

Drug Trial Radar · NCT07033234

Evaluate the Safety and Pharmacokinetics/Pharmacodynamics and Food Effect of HS-20118

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of HS-20118, and the Food Effect (FE) on the Pharmacokinetics in Adult Participants

Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 142 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

142

Planned (sponsor's estimate)

Start

May 16, 2025

Primary completion

Mar 2026

Study completion Mar 2026

Sponsor

Sponsor type
Industry
First posted
Jun 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study will be conducted in 2 parts (SAD and FE for Part 1 and MAD for Part2). Part 1 is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability, immunogenicity, and PK of HS-20118 and explore the food effect and fasting time on PK after a single oral dose in healthy participants. Part 2 is a multi-center, randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability, immunogenicity, PK, and PD of HS-20118 after multiple oral doses in patients with moderate to severe plaque psoriasis.

Conditions

  • Psoriasis

Interventions

  • HS-20118Drug

    HS-20118

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, sever ity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuationTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)
  2. Number of participants with abnormalities of physical examinationTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)
  3. Number of participants with abnormalities of vital signsTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)
  4. Number of participants with clinical laboratory abnormalitiesTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)
  5. Number of participants with abnormalities of electrocardiogram (ECG) parametersTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.